31 results
8-K
EX-10.1
AXLA
Axcella Health Inc.
13 Oct 22
Entry into a Material Definitive Agreement
8:15am
expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay
424B5
AXLA
Axcella Health Inc.
13 Oct 22
Prospectus supplement for primary offering
7:55am
operations, such as a cybersecurity incident; or one of our key executives, scientists or other personnel may become incapacitated by COVID-19
8-K
EX-10.1
bdzrz0w
16 Mar 22
Axcella Therapeutics Announces $25 Million Registered Direct Offering of Common Stock Priced At the Market
8:30am
424B5
v57ot1q1 gws
16 Mar 22
Prospectus supplement for primary offering
8:00am
S-3
EX-1.2
5z95op8tiw
5 Jun 20
Shelf registration
5:02pm
10-K
jg4en7 51ntrd59
23 Mar 20
Annual report
4:12pm